Clinical Trial: A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050368) titled 'A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers' on June 16.

Brief Summary: MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.

The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteer

Intervention: DRUG: Psilocybin

Capsule containing active ingredient, psilocybin

DRUG: Placebo

Capsule ...